文献速递浆细胞疾病

埃罗妥珠单抗联合来那度胺/地塞米松治疗复发或难治性多发性骨髓瘤:ELOQUENT-2随访及无进展生存期与肿瘤生长的事后分析

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
PubMed 文献 · Br J Haematol · 2017-07-05

ELOQUENT-2随机III期研究比较埃罗妥珠单抗联合来那度胺/地塞米松(ELd)与来那度胺/地塞米松(Ld)治疗复发/难治性多发性骨髓瘤,ELd较Ld降低疾病进展/死亡风险30%(HR 0.70)。3年扩展随访显示ELd较Ld降低疾病进展/死亡风险27%(HR 0.73;P=0.0014),总缓解率79% vs 66%(P=0.0002),中期总生存显示有利于ELd的趋势(P=0.0257),不良事件两组相当。

要点

  • ELd较Ld降低疾病进展/死亡风险27%(HR 0.73;P=0.0014)。
  • 总缓解率ELd 79% vs Ld 66%(P=0.0002)。
  • 中期总生存显示有利于ELd的趋势(P=0.0257),1年率91% vs 83%、2年率73% vs 69%、3年率60% vs 53%。

核心结论

  • ELd较Ld提供持久且具有临床相关性的疗效改善,增量毒性最小。

研究设计与样本

  • 随机III期ELOQUENT-2研究(NCT01239797),比较ELd与Ld在复发/难治性多发性骨髓瘤中的疗效与安全性。
  • 呈现3年扩展随访数据,终点包括无进展生存期、总缓解率和中期总生存。
  • 探索性事后分析包括诊断至治疗时间及既往治疗线数对无进展生存期的影响,以及血清M蛋白动态建模。

主要发现

  • ELd较Ld降低疾病进展/死亡风险30%(HR 0.70)。
  • 总缓解率ELd 79% vs Ld 66%(P=0.0002)。
  • ELd较Ld降低疾病进展/死亡风险27%(HR 0.73;P=0.0014)。
  • 中期总生存显示有利于ELd的趋势(P=0.0257);1年率ELd 91% vs Ld 83%,2年率ELd 73% vs Ld 69%,3年率ELd 60% vs Ld 53%。
  • 在诊断至治疗时间≥中位时间且既往仅一线治疗的患者中,ELd较Ld降低进展/死亡风险53%(HR 0.47)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The randomized phase III ELOQUENT-2 study (NCT01239797) evaluated the efficacy and safety of elotuzumab + lenalidomide/dexamethasone (ELd) versus lenalidomide/dexamethasone (Ld) in relapsed/refractory multiple myeloma. ELd reduced the risk of disease progression/death by 30% versus Ld (hazard ratio [HR] 0·70). Median time from diagnosis was 3·5 years. We present extended 3-year follow-up data. Endpoints included progression-free survival (PFS), overall response rate (ORR) and interim overall survival (OS). Exploratory post-hoc analyses included impact of time from diagnosis and prior lines of therapy on PFS, and serum M-protein dynamic modelling. ORR was 79% (ELd) and 66% (Ld) (P = 0·0002). ELd reduced the risk of disease progression/death by 27% versus Ld (HR 0·73; P = 0·0014). Interim OS demonstrated a trend in favour of ELd (P = 0·0257); 1-, 2- and 3-year rates with ELd versus Ld were: 91% versus 83%, 73% versus 69% and 60% versus 53%. In patients with ≥ median time from diagnosis and one prior therapy, ELd resulted in a 53% reduction in the risk of progression/death versus Ld (HR 0·47). Serum M-protein dynamic modelling showed slower tumour regrowth with ELd. Adverse events were comparable between arms. ELd provided a durable and clinically relevant improvement in efficacy, with minimal incremental toxicity.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dimopoulos MA, Lonial S, White D, et al. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017. PMID: 28677826. doi:10.1111/bjh.14787

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。